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Open access under the ElBackground: Cutaneous melanoma displays high morbidity and mortalit y rates. Isolated limb perfusio n
with melphalan (Mel) is used for the treatment of non-resectable, locally advanced extremity melano- 
mas. When combined with tumor necrosis factor alpha (TNF-alpha) treatment, the complete response 
varies between 70% and 90%. The mechanisms underlying the effects of Mel and TNF-alpha are not com- 
pletely understood . We evaluated the impact of systemic Mel and TNF-alpha administration on tumor 
growth, analyzed the morphological changes promote d by each treatment , and identiﬁed early expressed 
genes in response to Mel and TNF-alpha treatment, either alone or in combination, in a murine melanoma 
model.
Methods: Six- to eight-week-old male mice were subcutaneously inoculated with B16F10 melanoma cells 
and then intravenously injected with TNF-alpha, melphal an or a combination of both drugs when the 
tumors reached 1.0 cm2. Tumor growth was monitored every other day, and histological analysis was 
performed when the tumors reached 3.0 cm2. Total RNA was extracted from the resected tumors and sub- 
mitted to ampliﬁcation, labeling and hybridizat ion on an olig onucleotide microarray (Fox Chase Cancer 
Center). Tumor growth and histological parameters were compared using ANOVA. Survival curves were 
calculated using the Kaplan–Meier method. Two-way ANOVA was used to identify differentially 
expressed genes among the various treatments, and Dunn’s test was used for pair-wise comparisons.
Results: Systemic administration of Mel impaired tumor growth (p < 0.001), improved animal survival 
(p < 0.001), and decreased mitotic rate (p = 0.049). Treatment with TNF-alpha alone had no impact, nei- 
ther on tumor growth, nor on survival, but it increased necrosis (p < 0.024) and decreased mitotic rates 
(p = 0.001) in the tumors. Combined treatment with Mel and TNF-alpha had similar effects in tumor 
growth, survival, necrosis and mitotic rate as observed with individ ual treatments. Moreover, 118 genes 
were found differentially expressed by microarray analysis and 10% of them were validated by RT- real 
time PCR. In our model we found that the treatments regulate genes that play important roles in tumor- 
igenesis suc h as cell adhesion (Pard3, Pecam1, Ilk, and Dlg5), proliferation (Tcfe3 and Polr1e), cell motility 
(Kifap3, Palld, and Arhgef6), apoptosis (Bcl2l11), and angiogenesis (Flt1and Ptprj).
Conclusions: Our data reproduces, in mice, some of the features observed in melanoma patien ts treated 
with the combination of Mel and TNF-alpha. The identiﬁcation of genes with altered expression by these 
drugs both individually and in combination might help in the understanding of their mechanism of action 
and, as a consequence, improved strategies that could impact their clinical application.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.Prudente, 211 Hospital AC
900 São Paulo, SP, Brazil. Tel.:
. de Lima).
sevier OA license.1. Introductio n
Cutaneous melanom as are malignan t, radio- and chemores is- 
tant neoplasias that originate from melanocy tes. Although 
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high morbidity and elevated mortality rates (80%) [1]. Melanomas 
are the most common tumor among young women, the seventh 
most common cancer among women in general, and the ﬁfth most 
common tumor among men [2]. It has been estimated that 62,480 
new cases of melanom a occurred in the USA alone in 2009, of
which 8440 represented lethal cases. Surgical excision is the treat- 
ment of choice for this type of tumor; it is associate d with a 10- 
year survival rate of 89% for stage IB tumors and a 5-year survival 
rate of 40% for stage IIIC tumors [3]. Adjuvant treatment with inter- 
feron-gamm a reduces recurren ce rates but has no signiﬁcant im- 
pact on survival [4]. Two-thirds of patients with metastatic 
disease display loco-regiona l spreadin g, including satellitosis and 
in-transit metastas is, which includes 21% of all metastatic cases.
Amputation is the ﬁrst choice treatment for in-transit metastasis 
and unresectabl e, locally advanced melanoma, with long-lasting 
control rates of 21–33% [5]. As an alternative treatment, isolated 
limb perfusion (ILP) is a less morbid option that causes no mutila- 
tion [6], especially in the case of bulky (P3.0 cm) or multiple le- 
sions (P15 lesions) [7]. In this approach, melphalan (Mel), a
bifunctiona l alkylating agent that induces apoptosis [8], is the drug 
of choice, resulting in complete response rates of 40–50% [9,10].
Although melphalan is frequently used in the treatment of multi- 
ple myeloma, the systemic use of Mel in melanoma therapy is
not possible because the required doses are highly toxic. The efﬁ-
cacy of the ILP procedure relies on high intratum oral Mel concen- 
trations (20-fold higher than the systemic doses).
The combinati on of TNF-alpha and Mel increases complete re- 
sponse rates to up 90%, limb salvage rates to 84% [7,9–11] and 5-
year overall survival rates to 42%. These results are very similar 
to those associated with surgical managemen t (25–30%) [7].
Two randomized phase III trials evaluated the role of ILP in ad- 
vanced-stage limb melanomas. Fraker et al. (2002) (unpublished
data) have shown an increase in complete response rates, notably 
in larger tumors (58% vs. 19% in smaller tumors), for the TNF-alph a
plus melphalan arm of the trial. The other trial was negative for 
primary end-points but presented a non-statisticall y signiﬁcant
improvement in complete response rates after 6 months for the 
combination arm of the study. A larger number of patients who 
displayed a complete response to TNF-alph a plus melphalan after 
3 months maintained that response for 6 months in the combina- 
tion arm of the study [5].
The most accepted mechanism for this synergistic effect is that 
TNF-alpha promote s the detachment of the endotheli al cells of tu- 
mor vessels from the basal membrane, thereby increasing vascular 
permeabilit y, which in turn facilitates the penetration and intratu- 
moral accumulation of Mel [12,13]. The alterations in the tumors 
promoted by TNF-alpha also prompt tumoral vasculatur e to under- 
go erythrostasis, leukostasis, and intravascula r coagulation , which 
impair the afﬂux of nutrients and oxygen. This creates an environ- 
ment that is more susceptibl e (low pH) to Mel activity, which leads 
to tumor hemorrh agic necrosis [14–16]. Apart from this suggested 
mechanism regarding the combination of TNF-alpha and Mel, the 
cellular and molecular mechanisms underlying the alteration s pro- 
moted by these two molecules are not completely understood .
The use of Mel and TNF-alpha in combination in ILP suggests 
that the identiﬁcation of the molecular targets triggered by the 
combination of these two drugs may reveal putative pharmaco- 
logic targets for the systemic treatment of melanomas using lower 
doses of melphalan in combinati on with alternative agents that are 
less toxic than TNF-alpha.
In this study, we evaluated the impact of systemic Mel and TNF- 
alpha administration on tumor growth, analyzed the morphologi- 
cal changes promote d by each treatment, and identiﬁed the early 
molecular targets of Mel and TNF-alpha, either alone or in combi- 
nation, in a murine melanoma model.2. Material and methods 
2.1. Animals 
For all experiments , male C57BL/6 mice (9–10 animals per 
group, as indicated) of 6–8 weeks of age were used. The mice were 
maintain ed in individually ventilated cages housed in a clean, tem- 
perature -controlled room with a 12 h light/12 h dark cycle with ac- 
cess to sterilized food and water ad libitum . All procedures that 
involved animal experimentati on were approved by the Institu- 
tional Animal Care and Use Committee (animal ethics license num- 
ber 016/07) and were in accordance with the International Ethical 
Guidelines .
2.2. Cells 
B16F1 and B16F10 mouse melanoma cells were kindly provided 
by the Ludwig Institute for Cancer Research (São Paulo, Brazil) and 
by Dr. Ronaldo Travassos (São Paulo Federal University – São Paulo,
Brazil), respectively . The cell lines were maintained in RPMI med- 
ium (Gibco BRL) supplemented with 10% fetal calf serum (Cultilab),
2.0 mM L-glutamine (Sigma), and 40 lg/ml gentamici n (Schering-
Plough) at 37 C and 5% CO2. Sub-conﬂuent cultured cells (up to
four passages only) were detached with 0.02% trypsin, harvested 
in complete medium, washed and resuspended in PBS. Cell viabil- 
ity was assessed via Trypan blue assay, and only cultures with 
P90% viable cells were used for the experimental induction of tu- 
mors in mice. The melanoma cell lines K1735M2 and M2R, which 
were used in the preparation of the reference RNA, were a kind gift 
from Dr. Jan Vilcek (New York University Medical Center) and Dr.
Shigeko Sonehara (University of São Paulo) and were maintained 
in DMEM under the same condition s described above.
2.3. In vivo model 
For tumor implantation, mice were manually restrained and 
5.0  105 melanoma cells (in 100 lL PBS) were subcutan eously in- 
jected in both rear ﬂanks. Tumor growth was evaluated every 
2 days by direct measureme nt with a caliper, and tumor size was 
calculated as the product of the two greatest perpendicul ar diam- 
eters. Mice bearing tumors of 1.0 ± 0.3 cm2 (10 days after tumor 
implantati on) were randomly assigned to be intravenousl y in- 
jected with 100 lL of one of the following treatments: (i) Mel 
(n = 10), 12.0 mg/kg melphalan (Alkeran, Glaxo-Smith-Kl ine); (ii)
TNF-alph a (n = 10), 0.05 mg/kg recombinant murine TNF-alpha 
(R&D); and (iii) Mel + TNF-alpha (n = 9), the combination of the 
two agents at the aforementi oned doses. Control mice (n = 10)
were injected intravenousl y with 100 lL saline. The selected doses 
displayed no systemic toxicity when previousl y evaluated in vivo 
(data not shown). Three hours after treatment, the animals were 
anesthet ized with ketamine (Vetanarcol, König)/thiazine (Rompun,
Bayer) (60.0/15.0 mg/kg i.p.), and the tumors implanted on the left 
ﬂank were surgically removed. One portion of the harvested tumor 
was snap-frozen in liquid nitrogen for posterior RNA extraction,
and the other portion was ﬁxed in 10% phosphate-b uffered forma- 
lin (PBF) for histological analysis. The growth of the remaining 
right-ﬂank tumors was monitored every 2 days to assess the efﬁ-
cacy of each treatment. The mice were sacriﬁced when the tumors 
reached 3.0 cm2 to avoid animal suffering.
2.4. Histologica l analysis 
Tumor sections (5.0 lm thick) removed from the left ﬂanks and 
ﬁxed in PBF were stained with hematoxy lin–eosin. Digitalized 
images were obtained using an optical microscop e (Axioscope 40,
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each tumor slide, 10 non-overlap ping random ﬁelds were photo- 
graphed at high magniﬁcation (400). Images were blindly ana- 
lyzed using AxioVision software (version 3.1, Zeiss) by a single 
experienced pathologist. The following paramete rs were consid- 
ered: total tumor area, total melanom a cell count, and percentage 
of necrotic, hemorrhagic, and mitotic cells. Vascular density was 
assessed after immunosta ining for CD34 (SC7045, 1:100, Santa 
Cruz) using a 270  270 lm grid. For each sample, 20 non-overl ap- 
ping random ﬁelds were examined and every tubular structure 
with a clearly deﬁned lumen, which was lined with plain cells on
the reticulum grid, was counted (vascular structures were classi- 
ﬁed as either CD34+ or CD34 ). The tumor area was estimated 
by multiplying the percentage of the grid area occupied by the tu- 
mor and the total area of the grid.
2.5. RNA extraction, puriﬁcation, and ampliﬁcation 
Total RNA was isolated using Trizol reagent (Invitrogen, USA)
and a tissue disruptor (Polytron, Kinematika , Germany). After dis- 
ruption, the sample was spun at 12,000 g and 4 C to remove mel- 
anin. The RNA in the remaining clear pink suspension was then 
extracted as recommend ed by the manufacturer. Total RNA was 
puriﬁed using a RNeasy Midi Kit (Qiagen) following the manufac- 
turer’s recommendati ons, reverse-transcr ibed using ImProm-II™
RT (Promega) and oligo-dT (24)-T7 primers, and submitted to
two rounds of ampliﬁcation using a RiboMax kit (Promega) follow- 
ing the protocol proposed by Gomes et al. [17].
2.6. Microarray gene expression analysis 
We used ampliﬁed RNA (aRNA) isolated from 18 tumor samples 
(Control – 5 samples; Mel – 4 samples; TNF-alph a – 4 samples; and 
Mel + TNF-alpha – 5 samples) in the gene expression analysis by
microarray. For replica hybridization with dye swap, aRNA isolated 
from both the tumors and a pool composed of equal amounts of
RNA extracted from the K1735M2, M2R, B16F10, and B16F1 mela- 
noma cells were labeled with either Alexa Fluor 555 or Alexa Fluor 
647. The labeled aRNA samples were hybridize d against a glass 
platform containing 16,128 immobilized sense oligonucl eotides 
(Fox Chase Cancer Center, USA) corresponding to murine genes.
The pre-hybridi zation, hybridizatio n, and washing conditions are 
detailed in the online data Supplement . The slides were scanned 
with a confocal laser scanner (ScanArrayTM Express, Perkin–Elmer
Life Sciences, USA) with a 10 lm resolution and a PMT of 60% for 
Alexa Fluor555 and 70% for Alexa Fluor 647, and the data were ex- 
tracted with ScanArray Express software (Packard BioScience)
using the histogram method. Each slide generated a data set for 
each channel correspondi ng to the Alexa Fluor 555 and Alexa Fluor 
647 dyes. The locally weighted scatter-pl ot smoothing method 
(LOWESS), which was adjusted for linear and non-linear systemati c
variations, both of the intensity-de pendent types, and primarily for 
low intensity spots, was employed for data normalization. The 
complete array data set was deposited at NCBI Gene Expression 
Omnibus (GEO, http://www.ncbi .nlm.nih.gov/geo/ ) under series 
number GSE21559. The Pearson’s correlation coefﬁcient was used 
to determine the reproducibility of the experime nt in which dupli- 
cate hybridizatio ns were performed (main and dye swap), and the 
data are represented on a dispersion graph (MM plot). A two-way 
ANOVA was used to identify the differentially expressed genes 
among the various treatments , while Tukey’s test was used for 
pairwise comparisons. The comparisons were considered statisti- 
cally signiﬁcant when p 6 0.05. P values adjusted for multiple com- 
parisons (q value) were also calculated , assuming a false discovery 
rate (FDR) of 10%. The genes displaying a relative gene expression 
(fold) greater or equal to 1.5 were investigated further. For these analyses, the TM4-Microar ray Software Suite [18] and the R pack- 
age were employed.
2.7. Reverse transcription and real time PCR 
Two-thir ds of the samples employed in the real time PCR assays 
were derived from a different set of tumor samples than those used 
in the microarray, and the other one-third of the samples was de- 
rived from the same set that was used in the microarr ay (Control –
3 samples; Mel – 5 samples; TNF-alph a – 5 samples; and 
Mel + TNF-alpha – 5 samples). Two micrograms of total RNA were 
reverse-tr anscribed using ImProm-II™ RT reverse transcrip tase 
(Promega, USA) and oligo dT-primers accordin g to the manufac -
turer’s instructions. Speciﬁc primer sequence s and detailed quanti- 
tative real time PCR conditions are available in the online data 
Supplement. A pool of RNAs obtained from the saline-injected con- 
trol mice was used as reference, and the relative expression ratio 
was calculated in accordance with the protocol provided by Pfafﬂ
[19]. The housekeepin g gene hypoxanthi ne–guanine phospho ribo- 
syl-transferas e (Hprt) was used for normalization.
2.8. Statistica l analysis 
Tumor growth was compared among the groups and time 
points using repeated measures ANOVA followed by a post hoc Tu-
key-HSD test. ANOVA followed by Tukey’s test were employed to
compare the mean values of the photograp hed total tumor area, to- 
tal melanoma cell count, necrosis to total tumor area ratio, hemor- 
rhage to total tumor area ratio, and mitosis to total cell count ratio.
The mean values for the hemorrhage to total area ratio were com- 
pared using the Kruskal–Wallis test followed by Tukey’s test. The 
real time PCR data were compared via ANOVA followed by Tukey’s 
test or a Kruskal–Wallis test followed by a Mann–Whitney test, as
appropriate . Progression-fre e survival curves (the time required for 
the tumors to reach 3.0 cm2) were calculated using the Kaplan–
Meier method. The curves were compared using a log-rank test fol- 
lowed by the Cox regression method. A two-way ANOVA was used 
to identify the differentially expresse d genes among the various 
treatments, while the Dunn test was used for pairwise compari- 
sons. The statistical packages Statistica 5.0 and SPSS for Windows 
(version 15.0) were employed for these analyses. Results were 
deemed statistically signiﬁcant when p < 0.05.3. Results 
3.1. Impact of systemic Mel and TNF-alph a administr ation on tumor 
growth
Three hours after the treatment, the tumors of the left ﬂank
were surgically removed, and the growth of the remaining tumor 
(right ﬂank) was monitored until it reached 3.0 cm2. As shown in
the upper panel of Fig. 1, in mice treated with saline or TNF-alpha 
alone, a signiﬁcant increase in tumor size was observed between 
D0 (day of treatment initiation) and D6 (6 days after treatment ini- 
tiation) (p = 0.0001 for both). However, the systemic administra- 
tion of Mel promoted a delay in tumor growth, and no signiﬁcant
augment ation in the size of the tumors was observed between 
D0 and D6 in the groups treated with Mel alone (p = 0.052) or
Mel + TNF-alpha (p = 0.215). At D6, the tumors derived from mice 
treated with Mel or Mel + TNF-alpha were signiﬁcantly smaller 
than their saline- or TNF-alpha-inj ected counterpar ts (p < 0.001).
The addition of TNF-alpha at the dose adopted in this study did 
not improve the effect of Mel on tumor growth (p = 0.296 for Mel 
vs. Mel + TNF-alph a), and the signiﬁcant difference in the size of
the tumors in the Mel + TNF-alpha mice compare d with the 
Fig. 1. Impact of treatment with melphalan and Tnfa on melanoma tumor growth 
and progression-free survival in mice. Mice bearing tumors of 1.0 ± 0.3 cm2 were 
treated intravenously with saline (control group, n = 10), Tnfa (n = 10), melphalan 
(n = 10), or with associated treatment (Mel + Tnf, n = 9). Upper panel: results are 
shown as the mean and SEM of the tumor index obtained from the product of the 
two largest perpendicular transversal diameters of the tumors (tumor index).
Comparisons were done by ANOVA followed by Tukey’s test. Lower panel: Curves 
were calculated by Kaplan–Meier method and comparisons were done by log-rank 
test, followed by Cox-Regression. Mel + Tnf x Control HR = 0.034 95%CI 0.008–0.215,
p < 0.001. Mel  Control HR = 0.041 95%CI 0.006–0.18, p < 0.001. Tnf  Control 
HR = 0.28 95%CI 0.073–1.10, p = 0.069.
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(p = 0.006). No differenc es in the size of the tumors at D6 were ob- 
served between the control and TNF-alpha groups (p = 0.296). We
observed a reduced rate of tumor growth when comparing the 
Mel group with the TNF-alpha group (Mel vs. TNF-alpha, p = 0.10).
As shown in the lower panel of Fig. 1, the delay in tumor growth 
promoted by Mel impacted the progression -free survival (PFS) of
the Mel-treated mice. This delay was higher and statistically signif- 
icant compared with the controls, both in mice treated with Mel 
(HR = 0.041 95%CI 0.006–0.18, p < 0.001) and in those treated with 
Mel + TNF-alpha (HR = 0.034 95%CI 0.008–0.215, p < 0.001). Never- 
theless, there was no differenc e between the control and TNF-al- 
pha groups (p = 0.069), and no improvem ent in survival was 
observed when TNF-alpha was combined with Mel (p = 0.821 for 
the Mel and Mel + TNF-alpha groups).
The same treatment response was observed in mice bearing 
B16F1-impl anted tumors (see online data Supplement , Figs. 1
and 2).
3.2. Morphologic al changes promoted by the Mel and TNF-alph a
treatments
The photomicrogra phs displayed in Fig. 2 shows the main alter- 
ations in morphology observed in the tumors 3 h after treatment with Mel and TNF-alpha, as described earlier. In all groups that re- 
ceived Mel and/or TNF-alpha, we observed a decrease in the total 
number of mitotic cells compared with the control saline-treated 
group (Table 1 and online Supplement ary data Fig. 3). Increased 
levels of necrosis were observed in the groups treated with TNF-al- 
pha alone (p = 0.017) or in combinati on with Mel (p = 0.015) com- 
pared with the control group (Table 1 and Fig. 2). No difference was 
observed between the groups treated with TNF-alpha alone and 
Mel + TNF-alpha (p = 0.233).
Three hours after treatment, no modiﬁcation in vascular density 
was observed in response to any treatment (online Supplement ary 
data Table 1).3.3. Microarray gene expression proﬁling
A total of 596 elements that were differentially expressed 
among treatments were identiﬁed via ANOVA. Due to oligonucl eo- 
tide redundancy, these 596 elements corresponded to 118 genes (a
complete list is provided in the online data Supplement Tables 2
and 3). These 118 genes were used to create the non-superv ised 
hierarchical cluster shown in Fig. 3. In the image, color intensity 
is proportio nal to the log 2 of the sample to reference intensity ra- 
tio and varies from 3 to +3. The samples that received the same 
treatment grouped together almost perfectly, according to this 
set of genes. Using SOM (self organizing maps) analysis, it was pos- 
sible to identify subgroups of genes that displayed similar patterns 
of expression in response to each treatment (online data Supple- 
ment Table 4).
Real time PCR was used to validate the expression of 11 candi- 
date early targets that were different ially expresse d according to
the microarray analysis and showed relative expression rates of
at least P1.5. The candidates were arbitrarily selected to match 
10% of all differentiall y expressed genes. These genes included 
Pard3, Dlg5, Arhgef6, Flt1, Iﬁ202b, Cck, Ptprj, Pecam1, Irak1bp1, Palld,
and Bcl2l11 (Fig. 4). Seven of these genes (Pard3, Flt1, Ptprj, Dlg5, Ir-
ak1bp1, Iﬁ202b, and Cck) were either up- or downregulated in the 
same manner as that observed with the microarray in at least 
one of the groups. Among the genes selected for validation, two 
were different ially expresse d between Mel and Mel + TNF-alpha 
(Palld and Bcl2l11), and Mel and TNF-alpha (Palld) in the microarr ay
analysis (Fig. 4). Although Fabp4 was not identiﬁed as statistically 
different ially expressed as assessed via microarray, this gene dis- 
played the highest value of relative expression and a tendency to
be downregulated in the groups treated with TNF-alpha (online
data Supplement Fig. 4a). For this reason, Fabp4 expression was 
also evaluated via real time PCR, and this trend was conﬁrmed.4. Discussion 
The concomitan t administration of TNF-alph a and Mel in the 
treatment of locally advanced extremity melanoma increases the 
response rate and eventual ly extends the tumor control time 
(Deroose et al. 2011). A recent meta-analysis of twenty-two studies 
of ILP for the treatment of melanoma demonstrat ed that ILP is a
rather safe strategy with an acceptable overall survival (36.5% in
5 years) [20]. Nevertheles s, the mechanisms underlyin g its effects 
are not clear. To identify potential molecular targets that may al- 
low us to better understa nd the mechanism s involved in the inter- 
action of Mel and TNF-alpha in melanoma treatment, we studied 
the gene expression proﬁle of murine melanom as exposed to these 
therapeuti c agents. Our study revealed many interesting potential 
targets for the developmen t of therapeutic strategies that may be
used in the future to improve ILP results and for the systemic use 
of alkylating drugs, such as melphalan, in combination with alter- 
native agents that are less toxic than TNF-alph a.
Fig. 2. Representative microphotographs of hematoxylin–eosin stained major histological changes observed 3 h after treating melanoma with melphalan and Tnfa in mice.
Left upper panel: Control group (saline-treated animals). Tumor tissue architecture is preserved with no necrosis or hemorrhage area. Right upper panel: Although necrotic 
areas are observed in Melphalan-treated animals, the tissue architecture is preserved. Left lower panel: extensive necrotic areas (arrows) and dilated blood vessels with 
thrombus in their lumen () are observed in the tumors extracted from Tnfa-treated animals. Right lower panel: extensive necrosis (arrows) associated with blood vessel 
dilation, luminal thrombuses (), and impressive intercellular edema are presented in the tumors collected from mice treated with Mel + Tnf. All pictures were taken under 
magniﬁcation of 100 .
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extensive hemorrhagi c necrosis in tumors [21], in our study,
TNF-alpha did not promote signiﬁcant differences in hemorrhage 
or vascular density, which was most likely due to the short drug 
exposure time prior to tumor removal. Despite this observation,
the efﬁcacy of our different treatment regimens is reﬂected in
the impairment of tumor growth, the promotion of necrosis, and 
detectable changes in the gene expression proﬁle of the tumors.
The isolated treatment with Mel led to a delay in tumor growth 
and a decrease in the mitotic index. The primary effect observed 
by the addition of TNF-alpha was the increase in tumor necrosis.
Although TNF-alpha alone also reduced the mitotic rate and 
promoted massive tumor necrosis, these effects did not represent 
signiﬁcant tumor growth arrest or better progression-free survival,
which was most likely due to the rapid prolifera tion of tumor cell 
remnants in the peripher y of the necrotic areas. We and others [21]
have observed that in vitro , TNF-alpha does not exert a direct cyto- 
toxic or cytostatic effect on B16F10 or B16F1 cells (data not 
shown). In contrast, Mel was shown to be cytotoxic to B16F10 cells 
and inhibit tumor growth.
We identiﬁed a set of 118 genes that responded to systemic 
treatment with Mel and TNF-alpha; we hypothesize that some of
these genes play important roles in tumorigenesis and the Table 1
Histopathological parameters compared among mice treated intravenously with saline 
(Mel + TNF-alpha). All comparisons were performed in relat ion to the control group. An
comparisons among groups, and the results were considered statistically signiﬁcant when
Groups Analyzed tumor area (103 lm2) Total melanoma cell
Control 33.88 ± 3.86 78.6 ± 7.09 
Mel 33.1 ± 5.54 71.0 ± 5.43 
Tnf 33.5 ± 2.34 57.5 ± 8.51 
Mel + Tnf 32.89 ± 6.83 52.66 ± 5.32 mediation of antitumoral effects, such as cell adhesion (Pard3, Pe-
cam1, Ilk, and Dlg5), proliferation (Tcfe3 and Polr1e), cell motility 
(Kifap3, Palld, and Arhgef6), apoptosis (Bcl2l11), and angiogen esis 
(Flt1and Ptprj), which could be targeted for drug developmen t. A
non-supe rvised hierarchical cluster based on these 118 differen- 
tially expressed genes (Fig. 3) allowed us to sort the various 
treatment groups almost perfectly. The combinati on of Mel and 
TNF-alph a modulated the expression of 59 genes. By comparing 
our in vivo and in vitro data sets, we hypothesize that the primary 
targets of Mel activity are most likely the melanoma cells them- 
selves, while TNF-alpha seems to act preferentially on cells in the 
tumor micro-envir onment, as B16F10 cells receiving the same 
treatment in vitro did not display the gene modulation observed 
in the in vivo model (online data Supplement Fig. 5).
We centered our discussion on six (Arhgef6, Iﬁ202b, Igf2bp3,
Pard3, Flt1, and Cck (Table 2)) of the 11 genes that displayed a p va- 
lue P0.05 and a relative expression (fold) P1.5.
The Arhgef6 gene (Rac/Cdc42 guanine nucleotide exchange fac- 
tor 6) (Table 2 and online Supplementary data Table 3) was down- 
regulated by treatment with TNF-alpha alone or in combination 
with Mel. Our data and that reported by others [22–25] support
the idea that reduced ARHGEF6 levels may lead to increased vascu- 
lar permeabilit y, endotheli al cell detachment and enhanced (control), melphalan (Mel), TNF-alpha (TNF-alpha), or a combination of both drugs 
ANOVA or Kruskal–Wallis test followed by Tukey’s test was employ ed for multiple 
 p < 0.05 (). The results are expressed as the mean ± SEM.
 count Mitosis (%) Necrosis (%) Hemorrhage (%)
0.7 ± 0.15 8.2 ± 5.3 0.7 ± 0.51 
0.33 ± 0.16 ⁄ 18.22 ± 3.15 1.0 ± 0.6 
0.1 ± 0.1 ⁄ 33.1 ± 7.21 ⁄ 4.7 ± 2.91 
0.22 ± 0.14 ⁄ 34.56 ± 6.43 ⁄ 2.44 ± 1.63 
Fig. 3. Non-supervised hierarchical clustering based on differentially expressed 
genes as a function of the type of treatment. Samples were grouped according to
correlation distances among the 118 genes identiﬁed by ANOVA using a Pearson’s 
linear correlation test. Color intensity correlates with the sample to reference signal 
intensity ratio. In green are those genes in which expression was down-regulated 
by the treatment, and in red are those in which the expression was up-modulated.
Missed data are represented by grey boxes; sample identiﬁcation is on the top. On
the right are the gene symbols of the elements used to build the cluster. Samples:
tumors of 1.0 ± 0.3 cm2 recovered from C57BL/6 mice treated intravenously for 3 h
with saline (C), Tnfa 0.05 mg/kg (T), melphalan 12 mg/kg (M), or both (MT). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred 
to the web version of this article.)
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ARHGEF6 integrates multiprotei c complexes that mediate the formatio n of integrin clusters during the initial phases of cell adhe- 
sion to the extracellular matrix (ECM) [23], the establishment of fo- 
cal adhesion, thereby contributing to cell migration [26] and
invasion capacities [24]. ARHGEF6 is a positive modulator of Rho- 
like monomeric G-proteins (Rac1 and Cdc42) [25], which mediate 
the activation of NFKB by TNF-alpha [22]. Inhibition of Cdc42 
was shown to be associated with an elevation in caspase-3 activity 
and increased the susceptibility of HUVECs to apoptosis in
response to TNF-alph a [27]. The downregul ation of Arhgef6 by
TNF-alph a may play a role in PAK (p21-activated protein kinase)
inhibition, which has been shown to exert activity against thyroid 
cancer cell lines [28].
Pard3 (partitioning defective 3 homolog) was one of the 20
genes modulated by Mel alone in vivo . The downregulation of
Pard3 could contribute to the increased endotheli al permeabilit y
that favors the intratumoral accumulation of Mel. It is also possible 
that the low expression of Pard3 could impair the ability of mela- 
noma cells to correct the DNA damage induced by Mel, as PARD3 
has been recently shown to modulate the activity of DNA-depen -
dent protein kinase (DNA-PK) and PARD3 knockdow n enhances 
irradiation susceptibi lity and promotes inadequate DNA break re- 
pair [29].
Upregulated by Mel and TNF-alpha, the protein encoded by
Iﬁ202b (interferon activated gene 202B) inhibits NFKB and AP1 
activity and sensitizes 3T3 cells to apoptosis when exposed to
TNF-alph a [30]. IFI202B also inhibits cell proliferation and reduces 
tumorige nicity, invasivenes s, metastatic potential, and angiogen e-
sis [31]. As NFKB inhibition seems to be the primary mode of action 
of Iﬁ202b, drugs capable of promoting NFKB inactivation, such as
bortezomi b, should augment TNF-alph a efﬁcacy or reproduce 
some of its effect on tumors, as suggested by recent reports [32].
Igf2bp3 (insulin growth factor binding-p rotein 3) encodes IMP3 
(insulin-like growth factor II mRNA-binding protein 3), an oncofe- 
tal RNA-binding protein that is involved in cell growth and migra- 
tion during the early stages of embryogenes is, cancer cell 
prolifera tion, and metastasis [33]. The expression of IMP3 corre- 
lates with melanoma progression and can help to differentiate nevi 
from malignant lesions [34,35]. Igfbp3 levels were upregula ted by
Mel and TNF-alpha treatment in our model, with high relative gene 
expression ratios.
Cck (cholecystokinin) is an agonist of the gastrin and cholecys -
tokinin receptors CCK-R1, CCK-R2, and CCK-R3. The inhibition of
Cck expression in tumors, which was most likely mediated by
TNF-alph a in our model, may be associate d with tumor growth 
inhibition via a reduction of tumor cell motility and invasivenes s
or a blockade of tumor neo-angioge nesis. Various studies have 
shown that cholecystokinin promotes cell invasiveness, motility,
and proliferation in melanomas , biliary duct and pancreatic cancer,
and Ewing’s tumor cell lines. Additionally , its suppression inhibits 
neo-angioge nesis in melanoma xenograft models [36–38].
The role of the vascular endothelial growth factor receptor-1 
(FLT1/VEGFR1) in angiogenesis and hematopoiesis is not com- 
pletely understood, but it is possible that it acts as a decoy receptor 
or a suppressor of signaling via vascular endotheli al growth factor 
receptor-2 (KDR/VEGFR2) [39]. FLT1 may also induce macrophage 
migration and the recruitment of endotheli al cell progenito rs and 
may function as a strong positive regulator of angiogenesis during 
tumor growth [40]. FLT1 encodes FLT1, which binds VEGFA, VEGFB,
and PLGF (placental growth factor). The downregulation of FLT1 in
tumors exposed to TNF-alph a may be associate d with reduced pro- 
liferative activity of the tumor endothelium and, in consequence,
the inhibition of tumor growth. FLT1 has a ten-fold greater afﬁnity
for its ligands than KDR but signiﬁcantly weaker tyrosine kinase 
activity. However, under pathologi c conditions, in which PLGF 
expression is high, Flt1 may play an important role in neo-angio- 
genesis [41]. FLT1 inhibition may also explain, at least in part, the 
Fig. 4. Comparison between relative gene expression assessed by real time PCR and microarray. Boxes represent relative gene expression rate obtained with real time PCR 
(grey boxes) and microarray (white boxes) experiments. (A) Bcl2l11, (B) Arhgef6, (C) Ptprj, (D) Fabp4, (E) Dlg5, (F) Cck, (G) Irak1bp1, (H) Iﬁ202b, (I) Flt1, (J) Palld, (K) Pard3, (L)
Pecam1.
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Mel. As FLT1 activation correlates with the inhibition of dendritic 
cell maturati on and T cell proliferation, the release of dendritic 
cells from the suppressive effect of FLT1 may result in enhanced tu- 
mor antigen presentation and allow for a more efﬁcient and long- 
lasting response against the tumor [42,43]. FLT1 production is
associated with a worse prognosis in melanomas [44]. Patterson 
et al. [45] have demonstrated that TNF-alpha blocks VEGF-induc ed
DNA synthesis in human endothelial cells and reduces FLT1 and 
KDR expression levels. Gille et al. [46] have observed, using a mod- 
el employing B16 melanomas , that the full inhibition of tumor 
growth and lung metastasis is dependent on the inhibition of both 
FLT1 and KDR. Interestingl y, blocking FLT1 signiﬁcantly reduced 
CD45-positi ve inﬂammatory cell tumor inﬁltration. Therapie s di- 
rected towards PLGF or FLT1 are also very attractive, as suggested 
by the work of Fischer et al. [47].
Fabp4 encodes FABP4, a small protein that binds to lipophilic 
compounds , forming complexes that interact in the nucleus with 
Pparg (peroxisome prolifera tor-activated receptor gamma), there- 
by taking part in adipocyte differentiation , glucose homeostasis,
inﬂammation, and anti-prol iferative activity against various carci- 
noma types [48]. Although Fabp4 was not found to be different ially 
expressed in treated tumors compared with control tumors, we
examined this gene further via real time PCR, as it presente d the highest value of relative expression rates. Indeed, the Fabp4 gene
was downregulated in the groups treated with TNF-alpha. Reduced 
expression of FABP4 has been shown to correlate with a higher 
stage and histological grade in bladder cancer [49]. In contrast,
Fabp4 is induced by VEGFA and FGF2 and its knockdown abolishes 
the angiogenesis induced by these growth factors but not by FLT1 
ligands [50]. PPARG is an interesting pharmac ological target, as
there is growing evidence that suggests a pro-apoptoti c effect for 
some PPARG agonists [51] and a synergistic tumoricidal activity 
against melanoma when combined with bortezomi b [32].
Most certainly, the additional differentiall y expressed genes 
also play a role in this model, and further studies are necessary 
to better understa nd their function in the context of our experi- 
mental model.
5. Conclusion s
In this study, melphalan induced melanoma regression in a
murine model when administere d intravenousl y and was associ- 
ated with mitotic inhibition and a prolongatio n of time to tumor 
progression . TNF-alpha promoted extensive necrosis in the tumors,
but this was not associated with increased animal survival.
A set of 118 early expression genes was regulated in tumors by
treatment with melphalan, TNF-alpha or a combination of the two 
Table 2
Genes modulated by treatmen t with Mel , TNF-alpha, or both in melanoma. The genes listed here showed variations in their expression levels compared with controls. The 
complete list of differentially expressed genes is shown in the online Supplementary data (Table 3).
Comparison Mel/control Tnf/control Mel + Tnf/control 
Up-modulated genes Pdia6, Aff1, Oprm1, Efna3, Orc1l, Extl2 Ddx20 , Polr1e, Cdc7, Pms2 Iﬁ202b, Zc3hav1, Igf2bp3, Neb, Atpbd4, Lepre1, Trp73, Trim24,
Cdc7, Irak1bp1, Col4a3bp, Zfp622, 4930544g21rik, Polr1e,
Pou2f1, Camk2d, Btbd3, Efna3, Ubap1, Slc25a33, Tacc2,
Rps6ka3, Ube4b, Trpc2, Igsf4a, Mphosph10, Tcfe3
Down-modulated genes Crls1, Pard3, Dlg5, Mib2, Kif1b, Orf61,
Cdc37l1, Ltbp3, Mrp149, Mad1l1,
Bc017158, Acbd6, Pms2, Col4a6
Arhgef6, Ptprj, Cck, Mrpl49,
Cdc37l1, Ift122, Sdsl
Glul, Arhgef6, Aph1c, Flt1, Art5, Cck, Pecam1, Rnf135, Kifap3,
Napb, Glul, Tmem176b, Trpm1, Fbxw8, Tia1, Cdc37l1, Angel2,
E2f1, Atp6v1c1, 2310038h17rik, Rnf130, Cklf, Rbpms,
Tmem176b, Ift122, Abhd12, Pcolce, Mgll, Bc033915, Pccb, Sdsl,
Wbp1, Cpsf1
Genes up-regulated when compared to control group are listed in the upper line and those down-regulated in the bottom line. All genes listed below had p value 60.05 for the 
comparison against the control group and those with expression fold P2.0 are highlighted in bold.
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capable of segregati ng the tumors submitted to each of the afore- 
mentioned treatments .
Although our data display some limitations that are inherent to
the experimental model adopted, the results provide insight into 
very interesting potential therapeuti c strategie s that could repro- 
duce systemically, with lower toxicity, some of the synergist ic ef- 
fects of TNF-alpha and Mel that have been observed in ILP. Based 
on these results, experiments using mixed co-cultur es of mela- 
noma, macroph ages and endothelial cells are ongoing for func- 
tional validation. Treatment with a combinati on of drugs that 
target some of the proteins encoded by the genes discussed in this 
report may be utilized to both improve the overall antitumoral ef- 
fect of each isolated compound and minimize toxicity.
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